Current Pharmaceutical Design - Online First
Description text for Online First listing goes here...
1 - 20 of 131 results
-
-
Multi-Segmental Evaluation of Intestinal Permeability of Amlodipine at Two Dose Levels
Available online: 02 December 2025More LessBackgroundIntestinal permeability plays a crucial role in drug absorption, as it varies across different gastrointestinal regions, affecting the bioavailability of orally administered drugs. This variability, combined with dose-dependent absorption, influences the overall efficacy and pharmacokinetics of the drug.
ObjectiveThis study aimed to investigate the impact of three intestinal regions (jejunum, ileum, and colon) along with two different doses of amlodipine (AML) (5 mg and 10 mg) on its permeability.
MethodsAn optimized HPLC method was developed and validated for the simultaneous quantification of AML, metoprolol (MTP), and phenol red (PR), while a modified single-pass intestinal perfusion (SPIP) was used to assess AML permeability across different intestinal segments.
ResultsNet Water Flux (NWF) showed significant fluctuations, with high positive values in the colon, indicating distinct physiological responses in this region. The effective permeability (Peff) of AML varied across different intestinal segments and doses. In the jejunum and ileum, the Peff of AML decreased with increasing doses from 5 mg to 10 mg, while in the colon, Peff remained relatively stable. Peff values ranged from 3.50 × 10−4 cm/s for the 5 mg dose to 1.80 × 10−4 cm/s for the 10 mg dose in the jejunum, from 3.30 × 10−4 cm/s (5 mg) to 2.41 × 10−4 cm/s (10 mg) in the ileum, and from 6.65 × 10−4 cm/s (5 mg) to 6.79 × 10−4 cm/s (10 mg) in the colon.
ConclusionThis study demonstrated significant segmental and dose-dependent variations in the intestinal permeability of AML using the SPIP model in rats.
-
-
-
Review on Molecular Targeting, Pharmacological Action, and Advanced Biopharmaceutical Aspects for the Management of Alzheimer’s Disease
Authors: Ram Ajay Gupta, Rajni, Kamal Shah and Hitesh Kumar DewanganAvailable online: 05 November 2025More LessAlzheimer’s disease (AD) is an ongoing progressive neurodegenerative disorder that predominantly affects elderly individuals. A systematic literature search was conducted using electronic databases such as PubMed, Scopus, Web of Science, and Google Scholar. Peer-reviewed articles, clinical trial reports, and experimental studies published in English within the last 15 years were considered. The keywords used for the search included “Alzheimer’s disease,” “amyloid-beta,” “tau protein,” “neuroinflammation,” “immunotherapy,” “drug repurposing,” and “experimental treatment strategies.” It is the most common form of dementia, ultimately leading to death in advanced stages. Recent advances in AD have featured the expected role of anti-amyloid, anti-tau, and anti-inflammatory therapies. Nonetheless, these treatments are still in various stages of preclinical and clinical trials. Moreover, drug repurposing is another promising avenue to identify effective therapeutic alternatives for Alzheimer's disease. This review highlights the underlying pathophysiological mechanisms of AD along with the limits of existing treatments. It also includes two methodologies, specifically; active immunotherapy and passive immunotherapy. Active immunotherapy tactics include the administration of antigens to stimulate antibody production. Additionally, this study discusses several experimental drugs and novel pharmaceutical approaches for AD.
-
-
-
Novel Targets and Nanotechnology Approaches in Treating Vulvovaginal Candidiasis: Insights into Host-Microbe Interactions and Immunotherapy
Available online: 30 October 2025More LessThe aim of this article is to study recent developments in the management of vulvovaginal candidiasis (VVC) with emphasis on overcoming antifungal resistance and recurrent VVC by examining host-microbe interaction, new molecular targets, immunotherapeutic interventions, and nanotechnology-based strategies. This review integrates recent VVC pathogenesis, immune response, and therapeutic development literature with a focus on immunomodulation, vaccine development, and nanotechnology interventions. Literature on immunotherapy and nanoparticle-based drug delivery systems was comprehensively reviewed. Immunotherapeutic concepts, such as cytokine modulation and vaccine therapy candidates, hold promise to substitute or supplement current antifungals. Nanoparticles exhibit efficacy in advancing drug solubility, reaching fungal cells, and minimizing unwanted effects. The synergy between nanotechnology and immunotherapy provides combined advantages over the multiple drawbacks of current therapies. Although novel methodologies have shown strong promise, aspects of safety, clinical relevance, and regulatory issues continue to remain key challenges. Nanotechnology-based host-targeted immunotherapy is most probably going to transform the scenario of VVC treatment, especially in drug-resistant cases. Additional research is needed to elucidate molecular host-fungal interaction mechanisms, validate vaccine efficacy in the clinic, and design standardized, reproducible nanotherapeutic platforms. Personalized regimens of treatment through immunological and microbiome profiling can enhance long-term outcomes in VVC treatment.
-
-
-
Ni-Fe Nanoparticles from Eugenia jambolana Extract Show Enhanced Anti-Biofilm, Anti-Inflammatory, and Antioxidant Effects
Available online: 29 October 2025More LessIntroductionMetallic nanoparticles are of interest for their potent bactericidal and anti-biofilm effects within a favorable therapeutic index. This study reports the green synthesis of bimetallic nickel-iron (Ni-Fe) nanoparticles using Eugenia jambolana extract and evaluates their antimicrobial, anti-biofilm, anti-inflammatory, and antioxidant activities.
MethodsNi-Fe nanoparticles were synthesized using E. jambolana extract and characterized for crystalline structure, size, stability, zeta potential, and functional groups. Antimicrobial activity was tested against Gram-positive (Bacillus subtilis, Staphylococcus aureus), Gram-negative (Escherichia coli, Pseudomonas aeruginosa), and Candida albicans. Anti-biofilm potential was assessed via inhibition and dispersion assays, EPS quantification, and in situ visualization. Anti-inflammatory activity was measured through protein denaturation and nitric oxide scavenging assays, while antioxidant capacity was determined using DPPH and H2O2 scavenging tests.
ResultsCrystalline, stable Ni-Fe nanoparticles with favorable functional groups were obtained. At 200 µg/mL, they showed broad-spectrum antimicrobial activity. Biofilm formation was reduced by 50% at 250 µg/mL, and dispersion occurred at 10-50 µg/mL, with S. aureus most susceptible. EPS inhibition at 50 µg/mL was 78% (E. coli), 70% (P. aeruginosa), 73% (B. subtilis), and 91% (S. aureus). Visualization confirmed strong adherence to biofilms. At 250 µg/mL, protein denaturation inhibition reached 45%, nitric oxide scavenging 42.6%, DPPH scavenging 44%, and H2O2 scavenging 49%.
DiscussionNi-Fe nanoparticles exhibit strong antimicrobial, anti-biofilm, anti-inflammatory, and antioxidant activities, notably against S. aureus. High EPS inhibition and biofilm dispersion suggest potential against biofilm-associated, drug-resistant infections.
ConclusionGreen-synthesized Ni-Fe nanoparticles from E. jambolana show multifunctional bioactivities, offering promise for therapeutic applications targeting resistant and biofilm-related infections.
-
-
-
Association of Exposure to Brominated Flame Retardants with Hyperuricemia: A Mediation Analysis of Inflammatory Factors
Authors: Xiangdong Wen, Senbo An, Tao Yuan, Shilei Zhang, Shilong Lv, Laibo Zhang and Shui SunAvailable online: 29 October 2025More LessBackgroundThere is increasing evidence that environmental factors play an important role in the pathogenesis of hyperuricemia. However, the relationship between Brominated Flame Retardants (BFRs) and serum uric acid and hyperuricemia remains unclear.
MethodsThis study used data from 7996 National Health and Nutrition Examination Survey (NHANES) participants from 2005 to 2016. Ten BFRs, including PBB153 and PBDE28, were included in the analysis. Multivariate logistic regression, subgroup analysis, Spearman correlation analysis, Weighted Quantile Sum (WQS), and Bayesian Kernel Machine Regression (BKMR) were used to assess the association between BFRs and hyperuricemia. We also evaluated the mediating role of the Systemic Immunoinflammatory Index (SII) in the relationship between BFRs and hyperuricemia.
ResultsResults show that, after adjusting for all covariates, PBDE47, PBDE99, PBDE100, and PBDE154 were significantly associated with hyperuricemia risk. The results of the WQS regression and BKMR model showed a significant positive correlation between exposure to mixed BFRs and hyperuricemia risk. PBDE183 (weight: 38%) was found to have the highest weight in the mixture. Further mediating analysis showed that the relationship between PBDE28 and PBDE183 exposure and hyperuricemia risk was mediated by SII.
DiscussionExposure to BFRs increases the risk of hyperuricemia, which may be mediated by inflammation. Therefore, future research should further explore the potential mechanisms underlying the association between BFR exposure and hyperuricemia risk.
ConclusionExposure to BFRs may increase the risk of hyperuricemia. Large-scale prospective cohort studies and experimental research are needed to confirm the relationship between BFRs and hyperuricemia.
-
-
-
Technological Advancements in Drug Formulation and Delivery: Revolutionizing Therapeutic Outcomes
Authors: Tavleen Kaur, Dushyant, Twinkle Sharma and Ashwani K. DhingraAvailable online: 28 October 2025More LessIntegrating the most advanced technologies in drug formulation and delivery systems is revolutionizing modern healthcare, leading to improved treatment efficacy and patient outcomes. This study explains how new technologies are transforming the way drugs are manufactured and delivered. They include the use of advanced materials, nanotechnology, and biotechnology. Nanotechnology has also enabled the fabrication of targeted drug-delivery particles. Such particles would guarantee that drugs reach a specific tissue or cell, with notable minimization of side effects. The precise targeting of drugs is found to significantly enhance the effectiveness of treatment in fields, such as oncology and personalized medicine, among others. Breakthroughs can also be observed in the design of biologics, gene therapies, and monoclonal antibodies, resulting in highly targeted treatments for a wide range of diseases. Besides novel drug formulations, smart delivery devices have also been designed that not only control the location and rate of drug release, but also the timing of drug release. These include implantable pumps, which ensure more controlled and sustained drug release, bio-responsive hydrogels, medication-eluting stents, which ensure controlled and sustained drug release, and many more devices. This reduces the number of readjustments and increases the likelihood of patient compliance with the treatment plan. This study also discusses the role of digital technologies, such as wearables and AI-driven drug delivery systems, which continue to track patient responses and dosages to improve the outcomes of therapy. Such developments have marked a significant paradigm shift in pharmaceutical research, bringing highly personalized, secure, and effective treatment options to patients worldwide.
-
-
-
Analysis of Chemical Constituents of Jiaotai Pill Based on UPLC-Q-Exactive Orbitrap-HRMS Technology and Its Antidiabetic Type 2 Mechanism in Network Pharmacology
Authors: Tingting Liu, Xu Wang, Jing Liu, Saisai Yang, Qiyao Li, Jubin Zhang and Xiuhong WuAvailable online: 28 October 2025More LessIntroductionJiaotai Pill (JTP) is a Traditional Chinese Medicine (TCM) prescription that has demonstrated therapeutic effects against Type 2 Diabetes Mellitus (T2DM). However, its active antidiabetic components and underlying mechanism of action remain unclear. This study aimed to identify the bioactive components in JTP and elucidate their molecular targets and therapeutic pathways in T2DM.
MethodsChemical components of JTP were identified using ultra-high performance liquid chromatography coupled with Q-Exactive Orbitrap high-resolution mass spectrometer (UHPLC-Q-Exactive Orbitrap-HRMS) in both positive and negative ion modes. Data were processed with Compound Discoverer 3.2 (CD 3.2) data software and validated using literature sources. Network pharmacology analysis was performed via multiple databases, including the Traditional Chinese Medicine Systems Pharmacology Database, Uniport, PubChem, GenCards, String, and Cytoscape, to predict potential bioactive compounds and therapeutic targets. Key interactions were validated using molecular docking and molecular dynamics simulations.
ResultsA total of 104 compounds were identified in JTP. Network pharmacology analysis revealed 5 key antidiabetic components and 5 core targets. These targets are involved in biological processes including apoptosis regulation, cell proliferation, and protein phosphorylation, and are enriched in pathways such as neuroactive ligand-receptor interaction, PI3K-AKT signaling, and AGE-RAGE signaling. Molecular docking indicated strong binding affinity between dihydrochelerythrine and AKT1(-9.0 kcal/mol) and TNF-α (-6.7 kcal/mol). Molecular dynamics simulation demonstrated stable and sustained hydrogen bonding between dihydrochelerythrine and AKT1.
DiscussionDihydrochelerythrine, as an active ingredient in JTP, may exert its antidiabetic mechanism by binding with AKT1, but it needs to be verified by subsequent animal or cell experiments.
ConclusionDihydrochelerythrine, a key active component of JTP, may exert antidiabetic effects in T2DM through stable interaction with AKT1, highlighting a potential therapeutic mechanism.
-
-
-
Nephrotoxicity Evaluation of Green and Chemically Synthesized Copper Oxide Nanoparticles in Rats: A Biochemical and Genotoxic Approach
Authors: Sania Naz, Hussain Ali, Tajamul Hussain, Salman Alrokayan, Muhammad Zia, Ankita Acharya and Muhammad LatifAvailable online: 28 October 2025More LessIntroductionThis study aimed to synthesize and characterize copper oxide nanoparticles (CuO NPs) using Rhus punjabensis extract and chemical methodologies. The comparative nephrotoxicity of green-synthesized CuO NPs (G-CuO-NPs) and chemically synthesized CuO NPs (C-CuO NPs) were examined in Sprague-Dawley rats and their offspring following oral administration during pregnancy and lactation.
MethodsFourier Transform Infrared Spectroscopy (FT-IR), Scanning Electron Microscopy (SEM), Transmission Electron Microscopy (TEM), and X-ray Diffraction (XRD) were employed to examine the morphology, dimensions, and functional groups of the fabricated CuO NPs. To assess the relative nephrotoxicity of G-CuO-NPs and C-CuO-NPs at doses of 50 and 100 mg/kg, twenty-five rats were randomly allocated to five groups (designated as G1, G2, G3, G4, and G5), with each group comprising one male and four female animals for mating purposes. Nephrotoxicity of both parental and offspring animals was evaluated by examining their antioxidant status, total protein content, lipid peroxidation, genotoxicity, serum biochemistry, and histopathology.
ResultsFT-IR confirmed the synthesis of CuO NPs, while TEM and SEM revealed that G-CuO NPs were spherical and C-CuO NPs were oval. The XRD analysis showed that both NPs had a monoclinic structure. The crystalline dimensions of G-CuO NPs were 36.6 nm, and 32.85 nm for C-CuO NPs. C-CuO NPs showed dose-dependent toxicity in both parents and pups, causing a disturbance in the antioxidant balance, reducing protein content, and inducing lipid peroxidation and genotoxicity in the renal tissues. The morphological architecture of the parents’ kidneys and renal function were evaluated. G-CuO NPs, on the other hand, showed mild toxicity only in the parents.
DiscussionThe findings indicate that G-CuO NPs exhibit biocompatibility and are suitable for biological applications. This study underscores the compatibility of plant-derived metallic nanoparticles with living systems and paves the way for investigating their potential applications in contexts where toxicity limits the use of nanoparticles.
ConclusionBased on these findings, the biocompatibility of green-synthesized CuO NPs was determined, and they did not induce nephrotoxicity in both parents and their offspring. In contrast, chemically synthesized CuO NPs, when administered at higher concentrations, were found to cause nephrotoxicity, which may also be transmitted to the offspring through lactation.
-
-
-
Design and Synthesis of Novel Spiropyridine Derivatives as Promising Anti-inflammatory and Gene-targeting Agents Against COVID-19
Authors: Rita M. Borik, Mohammed A. Hussein, Hanan A.A. Farrag and Enas A. TahaAvailable online: 27 October 2025More LessBackgroundThe COVID-19 pandemic, caused by SARS-CoV-2, has highlighted the urgent need for effective antiviral and anti-inflammatory therapies. Spiropyridine derivatives containing a chalcone moiety have shown potential in targeting key enzymes involved in viral replication and inflammation.
ObjectiveTo evaluate the inhibitory effects of synthesized spiropyridine derivatives on SARS-CoV-2 main protease (Mpro), secreted phospholipase A2 (sPLA2), and cytosolic phospholipase A2 (cPLA2), and to assess their impact on inflammatory and oxidative stress markers in LPS-treated lung cells.
AimTo develop novel therapeutic agents that can effectively manage COVID-19 and related inflammatory conditions.
MethodsThe synthesized compounds (1-3) were tested for their inhibitory activity against SARS-CoV-2 Mpro, sPLA2, and cPLA2 using in vitro assays to determine IC50 values. Inflammatory markers (COX-2, IL-2, IL-4, TGF-1β, TNF-α) and oxidative stress markers (GSH, SOD, GR, MDA) were measured in LPS-treated lung cells. Gene expression levels of sPLA2 and cPLA2 were also assessed. Molecular docking studies were conducted to analyze the binding affinities and interactions of the compounds with the target enzymes.
ResultsCompounds 1-3 showed significant inhibitory activity against SARS-CoV-2 Mpro with IC50 values of 19.85 µM, 7.31 µM, and 3.73 µM, respectively. For comparison, baicalein's IC50 value was 13.63 µM. Additionally, these compounds inhibited sPLA2 with IC50 values of 8.36 µM, 7.31 µM, and 3.73 µM, and cPLA2 with IC50 values of 20.44 µM, 6.02 µM, and 4.61 µM, respectively. Baicalein's IC50 values for sPLA2 and cPLA2 were 11.73 µM and 5.89 µM, respectively. In LPS-treated lung cells, compounds 1-3 significantly reduced COX-2 by up to 90.12%, IL-2 by 74.19%, IL-4 by 79.51%, TGF-1β by 44.57%, and TNF-α by 68.49%. They enhanced GSH by up to 194%, SOD by 357.19%, and GR by 445.87%, while reducing MDA by 77.90%. Gene expression of sPLA2 and cPLA2 was significantly downregulated by up to 82.31% and 64.59%, respectively. Molecular docking studies revealed binding affinities of -28.20, -28.20, and -28.07 kcal/mol for SARS-CoV-2 Mpro; -16.72, -17.21, and -15.89 kcal/mol for sPLA2; and -65.66, -66.95, and -79.24 kcal/mol for cPLA2, respectively.
DiscussionThe results demonstrate that the structural integration of a spiropyridine core with a chalcone moiety yields compounds with superior multi-target inhibitory activity. The potent antiviral, anti-inflammatory, and antioxidant effects are significantly correlated with their strong binding interactions with the active sites of Mpro, sPLA2, and cPLA2, as validated by molecular docking. These findings align with and extend current research on targeting host-inflammatory pathways alongside viral replication for COVID-19 management.
ConclusionThe synthesized spiropyridine derivatives containing a chalcone moiety exhibit potent antiviral, anti-inflammatory, and antioxidant properties. These findings suggest that these compounds could be promising therapeutic agents for managing COVID-19 and related inflammatory conditions. Future studies should focus on in vivo experiments, clinical trials, and structural optimization to further develop these compounds for clinical use.
-
-
-
Gender-Based Disparities in Knowledge, Attitudes, and Practices Among Type-II Diabetes Patients in Punjab, India: Insights for Tailored Interventions
Authors: Sandeep Kaur, Sidharth Mehan and Ghanshyam Das GuptaAvailable online: 24 October 2025More LessIntroductionManaging Type II Diabetes Mellitus (T2DM) can be extremely difficult, especially in diverse populations where patient outcomes may be impacted by gender differences. Understanding patients' knowledge, attitudes, and practices (KAP) is essential for creating focused interventions. This study aims to evaluate the KAP of T2DM patients attending outpatient clinics in Moga, Punjab, India, with a focus on gender disparities.
MethodsA cross-sectional study was conducted among 500 T2DM patients (197 females and 303 males). Inclusion criteria were T2DM patients aged above 18 years, while pregnant and breastfeeding women were excluded. Data were analyzed using SPSS version 25, applying the Mann-Whitney U, Kruskal-Wallis, Chi-square, and Spearman’s correlation tests.
ResultsPoor knowledge and attitude scores were observed in 32.8% and 37.4% of patients, respectively, while 51.7% displayed fair practice scores. A gender-wise analysis revealed that males had higher proportions of good knowledge (33.7%) and attitude scores (50.2%) compared to females (20.8% and 36.0%, respectively). In terms of practice, both genders reported similar poor scores (31%).
DiscussionMales had significantly higher knowledge and attitude scores, with better awareness of T2DM risk factors, complications, and management strategies, likely due to higher educational attainment and greater access to healthcare resources, but both genders faced challenges in translating knowledge into self-care practices. Correlation analysis revealed a positive association between KAP scores and clinical parameters.
ConclusionThe study underscores the need for tailored educational programs that incorporate socio-cultural considerations and improved access to healthcare resources, which are crucial for bridging gender gaps in diabetes self-management.
-
-
-
Emerging Vector-Borne Nipah Virus Infection: Unexplored Hazards, Diagnostic Challenges, and the Potential of Phytomedicine-Based Therapeutics
Available online: 23 October 2025More LessIntroductionMillions of people have died from zoonotic illnesses, like COVID-19 and Nipahvirus infection (NiV), throughout history. Fruit bats (Pteropus sp.) are the main reservoir host for NiV, an RNA virus belonging to the Henipavirus group, which causes extremely infectious illnesses, such as COVID-19. NiV outbreaks have posed significant public health concerns, especially in South and Southeast Asia. The Nipah virus (NiV) infection is caused by a virus that belongs to the Paramyxoviridae family's Henipavirus genus. It is the source of zoonosis, which causes respiratory and neurological symptoms.
MethodsThis study has reviewed the epidemiology, pathophysiology, genetic diversity, and phylogenetics of NiV. It has explored NiV’s clinical features, cellular monitoring, infection factors, and the virus’ reservoir host.
ResultsPhylogenetic analysis has identified two circulating NiV lineages. Additionally, the study has examined the role of phytochemicals in combating viral infections. Despite the absence of a focused therapy for COVID-19, phytochemicals have been investigated for their potential antiviral properties. Evidence suggests that plants and their components may possess resistance against NiV by modulating the immune system and inhibiting viral replication.
DiscussionThe investigation into plant-derived compounds has offered a novel direction for NiV treatment, potentially enhancing viral resistance through immune modulation. Continued research on natural antivirals could bridge current gaps in therapeutic options for emerging zoonotic diseases.
ConclusionThe study has highlighted the transmission risk, detection challenges, and the potential of phytochemicals in managing NiV infections. The therapeutic potential of plants and their antiviral properties offer promising insights into future treatments for serious viral diseases, like NiV.
-
-
-
A Review of the Impact of Green Tea (Camellia sinensis L.) on Oral Health
Available online: 23 October 2025More LessIn recent years, green tea (Camellia sinensis) has garnered significant attention for its potential health benefits, including its benefits for oral hygiene. Green tea contains several bioactive components, including catechins, polyphenols, and fluoride, which contribute to its antibacterial, anti-inflammatory, and antioxidant properties. This review examines the bioactive components of green tea, specifically catechins, polyphenols, and fluoride, which possess numerous biological effects, including oral health benefits. As a result of its ability to neutralize volatile sulfur compounds, green tea inhibits the growth of cariogenic bacteria, such as Streptococcus mutans, reduces plaque development, and inhibits the development of halitosis. Recent evidence suggests that epigallocatechin-3-gallate (EGCG) has significant potential for oral health benefits. Furthermore, its anti-inflammatory effects help reduce gingival inflammation and oxidative stress, thereby easing the symptoms of periodontal disease. Numerous studies have shown that EGCG inhibits the growth of oral squamous cell carcinoma through mechanisms that include the induction of oxidative stress and apoptosis in cancer cells, as well as the inhibition of tumor invasion. This review discusses the potential mechanisms by which green tea promotes oral health and its therapeutic applications in dentistry. The literature review suggests that green tea may have potential as an adjunctive therapy for preventing and managing dental complications. However, more comprehensive pre-clinical and clinical studies are necessary to validate its efficacy. Furthermore, factors such as individual variability, patients' oral health conditions, long-term outcomes, and alterations in the oral microbiome require thorough investigation.
-
-
-
Synthetic Polymer-Based Interventions in Wound Healing: A Clinical Perspective on their Efficacy and Limitations
Available online: 23 October 2025More LessIntroductionWound healing is a complex and dynamic biological process involving hemostasis, inflammation, proliferation, and tissue remodeling. Conventional wound dressings provide only passive protection and fail to maintain an optimal healing microenvironment. Synthetic polymers, such as polyvinyl alcohol (PVA), polycaprolactone (PCL), poly(lactic-co-glycolic acid) (PLGA), and polyethylene glycol (PEG), have emerged as promising materials in advanced wound care due to their tunable physicochemical properties, biocompatibility, and enhanced therapeutic functionality.
AimThis review aims to evaluate the potential of synthetic polymers in wound healing applications, focusing on their structural and functional advantages, challenges, and opportunities in the development of next-generation wound dressings.
MethodologyA comprehensive literature review was conducted on recent developments in polymer-based wound dressings. In this review, we conducted a systematic literature search across Google Scholar, ScienceDirect, Scopus, Web of Science, and PubMed for publications between 2015 and 2025. The search strategy employed keywords, such as “wound healing”, “polyvinyl alcohol”, “polycaprolactone”, “poly(lactic-co-glycolic acid)”, “polyethylene alcohol”, “physicochemical characteristics”, “drug delivery capabilities”, and ” clinical trial” to capture the research landscape.
ResultsSynthetic polymers demonstrated significant potential in overcoming limitations of natural biomaterials, such as poor mechanical strength and rapid degradation. PEG-based hydrogels exhibited excellent hydrophilicity and sustained drug release. PCL scaffolds offered mechanical durability and supported tissue regeneration. PLGA allowed controlled therapeutic release through tunable degradation, while PVA ensured prolonged wound protection due to its structural stability. Polymer modifications, including crosslinking and blending, further enhanced wound healing efficacy.
ConclusionSynthetic polymers provide versatile platforms for designing multifunctional wound dressings with improved healing outcomes. Future research should emphasize biodegradable, patient-specific, and smart wound dressings integrating controlled drug delivery, infection prevention, and angiogenic stimulation, thereby revolutionizing wound management practices.
-
-
-
N-acetyl Cysteine Reduces Behavioral Disorders of the First and Second-generation Weaned Mice through the Modulation of TAC and the DNMT1 Gene Expression in the Hippocampus
Available online: 22 October 2025More LessIntroductionThis research aimed to reveal the role of antioxidants and DNMT1 gene expression in behavioral disorders after exposure to stress.
MethodsForty-eight male and female mice (weight 25-35 grams) were used. Their pups (weight 18-22 grams) were divided into 6 groups (n=20), Control, Social isolation stress (SIS), and SIS + N-acetylcysteine (NAC) 150 mg/kg intraperitoneally for male and 3 similar groups for female subjects, eight mice from each group were used for the first-generation experiments and another for mating and producing the second generation. The second-generation pups were designated into 9 groups A to I. After conducting behavioral tests of the Morris water maze (MWM) and shuttle box, they were anesthetized, decapitated, and their brains were removed. The neuronal counts of CA1 and CA3 were performed. DNMT1 gene expression, total antioxidant capacity (TAC), and malondialdehyde (MDA) of the brain were measured.
ResultsSpatial memory, passive avoidance, and TAC decreased in the SIS groups. MDA and DNMT1 gene expression of the SIS groups increased (p<0.001). Dead neurons in the CA1 and CA3 regions increased in the SIS group (p<0.001).
DiscussionAccording to the results of this study, N-acetylcysteine enhanced learning and memory while reducing neuronal death by decreasing oxidative stress. Additionally, it lowered the expression of the DNMT1 gene, which plays a crucial role in DNA methylation.
ConclusionAfter studying the human population, N-acetylcysteine may be introduced as an adjunct therapy to help mitigate the effects of stress.
-
-
-
Syringic Acid as a Potential Anticonvulsant Agent: Mechanistic Perceptions into Nitrite and Oxidative Stress Balance in the Prefrontal Cortex
Available online: 21 October 2025More LessIntroductionNitrergic transmission and oxidative stress are complicated factors in the seizure’s pathophysiology. Syringic acid has been revealed to exert numerous pharmacological properties, including neuroprotective effects. Hence, this research was designed to explore the anticonvulsant effects of syringic acid, focusing on its possible impact on nitrergic transmission and oxidative stress in the prefrontal cortex (PFC) in mice that underwent induction of seizure using pentylenetetrazole (PTZ).
MethodsForty male NMRI mice were randomly divided into five groups, including mice that received saline containing Tween 80 at a concentration of 1% (10 ml/kg), syringic acid at doses of 10, 20, and 30 mg/kg, and diazepam (10 mg/kg). Syringic acid was dissolved in saline containing Tween 80 at a concentration of 1%. All drugs were injected intraperitoneally one hour before seizure induction by PTZ. Seizure threshold, total antioxidant capacity (TAC), nitrite, and malondialdehyde (MDA) levels, as well as inducible nitric oxide synthase (iNOS) and neuronal nitric oxide synthase (nNOS) gene expressions, were assessed in the PFC.
ResultsSyringic acid increased the seizure threshold and TAC, whereas it decreased MDA and nitrite levels in the PFC samples. Furthermore, syringic acid diminished the expression of iNOS and nNOS genes in the PFC.
DiscussionOxidative/nitrosative stress, which is involved in the pathophysiology of seizure, was alleviated by syringic acid.
ConclusionIt was concluded that, at least partially, the anticonvulsant property of syringic acid was mediated through the mitigation of oxidative stress and nitrergic transmission in the PFC in PTZ-induced seizures in male mice.
-
-
-
Mechanistic Insights into Qiangjie Xinyi Decoction for Northwest Dryness Syndrome with Allergic Rhinitis: Network Pharmacology and Experimental Validation Methods
Authors: Yue-Lin Zhang, Ling Tie, Xian-Jie Zhen, Jin-Fang Dou, Ru-Xue Deng, Si-Yu Tao, Nan-Nan Liu, De Jiang and Guang-Jian JiangAvailable online: 20 October 2025More LessIntroductionQiangjie Xinyi Decoction (QJXYD) has been effectively utilized in the clinical treatment of Northwest Dryness Syndrome (NDS) with allergic rhinitis (AR). However, its therapeutic effect lacks a theoretical basis. This study employs network pharmacology and experimental validation to investigate the therapeutic potential of QJXYD on NDS with AR and elucidate its mechanism of action.
MethodsDatabases such as TCMSP, OMIM, Genecards, etc. were used to obtain relevant targets for traditional Chinese medicine and diseases. A protein interaction network (PPI) was constructed in the STRING database to screen the core targets of QJXYD for the prevention and treatment of AR. A drug-disease-pathway network diagram was constructed using Cytoscape 3.9.0 to identify the main active ingredients that exert efficacy. Gene Ontology (GO) and KEGG pathway enrichment analyses were performed using the DAVID database. The significant findings were subsequently validated through molecular dynamics simulations. An NDS was established with the AR model in rats, and the network pharmacology results were validated through in vivo experiments.
ResultsThe key targets screened for PPI network construction included IL-6, TNF, VEGFA, etc. Key components such as quercetin, luteolin, and beta-sitosterol were explored in the component target pathway network diagram. GO functional enrichment mainly involved protein binding, inflammatory response, and other functions. KEGG enrichment analysis included pathways such as Th17 cell differentiation and the HIF-1 signaling pathway. Molecular docking and molecular dynamics simulations validated the research results. Animal experiments showed that QJXYD can reduce the protein and gene expression of IL-6, TNF, and VEGFA in the nasal mucosal tissue of NDS with AR rats.
DiscussionThis study, utilizing network pharmacology and animal experiments, found that QJXYD may target IL-6, TNF, and other targets through components such as quercetin, thereby regulating inflammation-related pathways to treat AR. Animal experiments confirmed that it can reduce the expression of key targets in the nasal mucosa. The research system revealed the mechanism of the compound, but there are limitations, such as unverified predictions and insufficient clinical representativeness of the model, which require further research.
ConclusionQJXYD can treat NDS with AR through multiple components, targets, and pathways, providing a theoretical basis for further research.
-
-
-
Otic Drug Delivery Systems: Current and Future Perspectives
Authors: Evren Algın Yapar, İmren Esentürk-Güzel, Merve Nur Özdemir and Lüceyn AbdoAvailable online: 17 October 2025More LessMany people worldwide suffer from various ear diseases, and their treatments are still challenging. The tympanic, round, and oval windows, and the blood-perilymph barrier are the three main physical obstacles to drug delivery. Conventional methods, such as oral administration or injections, often fail to overcome these obstacles. However, local drug delivery systems present a potential solution by reducing side effects and allowing higher drug concentrations to reach the inner ear. Numerous drug delivery techniques and patents have been evaluated in clinical and research settings in recent years. Even though otic drug delivery has evolved, there are still a number of issues, and further study is required to maximize these therapeutic modalities for clinical use. This review summarizes various local drug delivery techniques. Current barriers in otic drug delivery are highlighted, as well as innovative systems for future clinical applications.
-
-
-
Research on Anti-tumor Pharmacodynamics of Multi-functional Magnetic Lipid Polymer with Specific Targeted Transmission of siRNA and its Toxicity Evaluation
Authors: Yaru Liu, Chang Wang, Jie Jin, Jishan Quan and Guangyu JinAvailable online: 17 October 2025More LessIntroductionHepatocellular carcinoma (HCC) is the third leading cause of cancer deaths globally. Traditional treatments face limitations like low effectiveness, poor specificity, and significant side effects. Gene therapy, particularly siRNA-based, is promising for targeted gene regulation but requires effective delivery systems due to the instability and poor target delivery of unmodified siRNA.
MethodsThis study examined the storage and biological stability of LP-PEI-SPION (LPS) and GPC3-LP-PEI-SPION (GLPS). The potential of these agents as tumor imaging contrast agents and the targeting ability of gene delivery carriers were assessed through ex vivo organ fluorescence imaging and in vivo tumor magnetic resonance imaging (MRI). Antitumor efficacy was evaluated through tumor volume, protein blotting, immunohistochemistry, and TUNEL assays. In vivo safety was evaluated using HE staining, nude mouse weight changes, and blood biochemical indicators.
ResultsLPS and GLPS both formed stable siRNA complexes. GLPS showed excellent tumor targeting in vivo. MRI results showed that the GPC3-targeting peptide effectively enhanced the MR imaging performance and diagnostic accuracy. Tumor volume and weight measurements demonstrated potent tumor inhibition by GLPS/siRNA. Immunoblotting and immunohistochemistry revealed significant GPC3 reduction in the GLPS/siRNA-targeted group. Safety evaluations confirmed good biocompatibility for both LPS/siRNA and GLPS/siRNA.
DiscussionGLPS/siRNA demonstrates superior in vitro transfection and anti-tumor efficacy compared to LPS/siRNA. It exhibits high tumor fluorescence signals, reduced MRI T2 relaxation time, and effective tumor enrichment, providing MRI imaging capability. Safety assessments, including HE staining, body weight, and blood biochemistry, indicate good biocompatibility. The development of siRNA-based therapeutics has progressed, yet challenges remain, such as siRNA's susceptibility to degradation and poor membrane permeability. While carriers like liposomes and polymers are used, they have limitations. Nanoparticles that enhance endosomal/lysosomal escape and promote cytoplasmic siRNA release are needed to improve delivery efficiency, reduce off-target effects, and enhance safety.
ConclusionGLPS/siRNA demonstrates good stability, tumor targeting, imaging capability, and antitumor efficacy with favorable safety, positioning it as a promising theragnostic platform for HCC. This integrated system provides novel clinical tools for diagnosis and treatment, establishes a foundation for clinical translation, and enables simultaneous tumor imaging and gene therapy—offering innovative strategies for combined tumor theranostics.
-
-
-
Emerging Biomarkers for Early Detection and Prognosis of Liver Diseases
Authors: Jyoti Yadav, Avijit Mazumder and Saumya DasAvailable online: 16 October 2025More LessIntroductionThe purpose of this research is to review and evaluate both traditional and emerging biomarkers used in the diagnosis, monitoring, and treatment of liver diseases. The study aims to highlight how these biomarkers—such as liver enzymes, microRNAs, exosomes, and fibrosis-related proteins—can improve early detection, track disease progression, and support personalized treatment strategies for better patient outcomes.
Materials and MethodsThis study uses a literature review to analyze both traditional (ALT, AST, ALP, bilirubin, etc.) and emerging biomarkers (microRNAs, exosomes, CRP, IL-6, MMPs, TIMPs) in liver disease. It focuses on their role in diagnosis, disease monitoring, and personalized treatment planning.
ResultsTraditional biomarkers (ALT, AST, ALP, bilirubin, albumin) are key for liver function assessment. Emerging markers like microRNAs, exosomes, MMPs, and TIMPs improve early detection and disease monitoring. Together, they enhance diagnostic accuracy and support personalized treatment.
DiscussionThe combination of traditional and novel biomarkers improves early detection, accurate diagnosis, and personalized treatment of liver diseases. New biomarkers, such as microRNAs and exosomes, offer higher sensitivity and specificity, enabling non-invasive diagnostics. The findings align with current research trends that promote the use of molecular and extracellular markers. These biomarkers provide deeper insights into liver disease mechanisms, particularly in fibrosis and hepatocellular carcinoma.
ConclusionTraditional biomarkers are essential for liver assessment, while new ones like microRNAs, exosomes, MMPs, and TIMPs improve early diagnosis and monitoring. They support personalized care but need further validation for routine use.
-
-
-
Integrating Telemedicine, Virtual Environments, and AI in Digital Healthcare: Advances and Future Directions
Available online: 14 October 2025More LessObjectivesThe delivery of healthcare services via information and communication technology, or telemedicine, has grown to be an essential part of modern medicine. This study explores the evolving role of telemedicine, focusing on its expansion into the Metaverse, and evaluates its potential to improve healthcare accessibility, patient engagement, and medical outcomes.
MethodsA comprehensive analysis of the literature was conducted, evaluating studies investigating the efficacy of telemedicine in different medical fields, notably mental health, chronic disease management, and post-surgical follow-ups. This study assessed the impact of emerging technologies, specifically virtual reality (VR) and augmented reality (AR), on telemedicine, emphasizing their applications within the Metaverse. Furthermore, ethical considerations, insurance limitations, and technological disparities were assessed.
ResultsTelemedicine has significantly enhanced healthcare access, especially in remote and underserved regions. Patient satisfaction and purpose to continue with telemedicine services are elevated, particularly in specialized areas like Tele-stroke and mental health counseling.
DiscussionThe Metaverse has the potential to transform telemedicine through the establishment of immersive and interactive healthcare settings. VR and AR have the potential to facilitate virtual consultations, enhancing the interaction between patients and healthcare professionals. Additionally, the integration of data may lead to improvements in diagnostic accuracy and treatment planning. However, issues such as data privacy, cybersecurity hazards, and the digital gap must be addressed to provide adequate access.
ConclusionTelemedicine has demonstrated significant utility within modern healthcare, and its incorporation with the Metaverse offers novel prospects for improving patient care, advancing medical education, and facilitating collaborative research. Despite the promising benefits, it is crucial to address technological, ethical, and regulatory challenges to ensure widespread adoption and successful implementation.
-